218 related articles for article (PubMed ID: 26595674)
1. Synthesis of a Liposomal MUC1 Glycopeptide-Based Immunotherapeutic and Evaluation of the Effect of l-Rhamnose Targeting on Cellular Immune Responses.
Karmakar P; Lee K; Sarkar S; Wall KA; Sucheck SJ
Bioconjug Chem; 2016 Jan; 27(1):110-20. PubMed ID: 26595674
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.
Sarkar S; Salyer AC; Wall KA; Sucheck SJ
Bioconjug Chem; 2013 Mar; 24(3):363-75. PubMed ID: 23444835
[TBL] [Abstract][Full Text] [Related]
3. Augmenting Vaccine Immunogenicity through the Use of Natural Human Anti-rhamnose Antibodies.
Hossain MK; Vartak A; Karmakar P; Sucheck SJ; Wall KA
ACS Chem Biol; 2018 Aug; 13(8):2130-2142. PubMed ID: 29916701
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of a single-molecule L-rhamnose-containing three-component vaccine and evaluation of antigenicity in the presence of anti-L-rhamnose antibodies.
Sarkar S; Lombardo SA; Herner DN; Talan RS; Wall KA; Sucheck SJ
J Am Chem Soc; 2010 Dec; 132(48):17236-46. PubMed ID: 21080675
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Immunological Evaluation of a Single Molecular Construct MUC1 Vaccine Containing l-Rhamnose Repeating Units.
Hossain MK; Vartak A; Sucheck SJ; Wall KA
Molecules; 2020 Jul; 25(14):. PubMed ID: 32659971
[TBL] [Abstract][Full Text] [Related]
6. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
7. Liposomal Fc Domain Conjugated to a Cancer Vaccine Enhances Both Humoral and Cellular Immunity.
Hossain MK; Vartak A; Sucheck SJ; Wall KA
ACS Omega; 2019 Mar; 4(3):5204-5208. PubMed ID: 30949616
[TBL] [Abstract][Full Text] [Related]
8. Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine.
Hanisch FG; Ninkovic T
Curr Protein Pept Sci; 2006 Aug; 7(4):307-15. PubMed ID: 16918445
[TBL] [Abstract][Full Text] [Related]
9. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
Pietersz GA; Li W; Osinski C; Apostolopoulos V; McKenzie IF
Vaccine; 2000 Apr; 18(19):2059-71. PubMed ID: 10706970
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice.
Ryan SO; Vlad AM; Islam K; Gariépy J; Finn OJ
Biol Chem; 2009 Jul; 390(7):611-8. PubMed ID: 19426130
[TBL] [Abstract][Full Text] [Related]
11. Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.
Wu X; Yin Z; McKay C; Pett C; Yu J; Schorlemer M; Gohl T; Sungsuwan S; Ramadan S; Baniel C; Allmon A; Das R; Westerlind U; Finn MG; Huang X
J Am Chem Soc; 2018 Dec; 140(48):16596-16609. PubMed ID: 30398345
[TBL] [Abstract][Full Text] [Related]
12. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses.
Guan HH; Budzynski W; Koganty RR; Krantz MJ; Reddish MA; Rogers JA; Longenecker BM; Samuel J
Bioconjug Chem; 1998; 9(4):451-8. PubMed ID: 9667946
[TBL] [Abstract][Full Text] [Related]
13. Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.
Madsen CB; Petersen C; Lavrsen K; Harndahl M; Buus S; Clausen H; Pedersen AE; Wandall HH
PLoS One; 2012; 7(11):e50139. PubMed ID: 23189185
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.
Supekar NT; Lakshminarayanan V; Capicciotti CJ; Sirohiwal A; Madsen CS; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
Chembiochem; 2018 Jan; 19(2):121-125. PubMed ID: 29120508
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope.
Brooks N; Hsu J; Esparon S; Pouniotis D; Pietersz GA
Molecules; 2018 Sep; 23(9):. PubMed ID: 30200528
[TBL] [Abstract][Full Text] [Related]
16. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
[TBL] [Abstract][Full Text] [Related]
17. Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1.
Ding C; Wang L; Marroquin J; Yan J
Blood; 2008 Oct; 112(7):2817-25. PubMed ID: 18669871
[TBL] [Abstract][Full Text] [Related]
18. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses.
Ryan SO; Turner MS; Gariépy J; Finn OJ
Cancer Res; 2010 Jul; 70(14):5788-96. PubMed ID: 20587526
[TBL] [Abstract][Full Text] [Related]
19. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
[TBL] [Abstract][Full Text] [Related]
20. The development of synthetic antitumour vaccines from mucin glycopeptide antigens.
Gaidzik N; Westerlind U; Kunz H
Chem Soc Rev; 2013 May; 42(10):4421-42. PubMed ID: 23440054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]